Allarity Therapeutics (ALLR) Cash from Financing Activities (2020 - 2026)

Allarity Therapeutics (ALLR) has 7 years of Cash from Financing Activities data on file, last reported at $19.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 77.15% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.2 million (down 58.66% YoY) and the FY2025 annual result came in at $10.6 million, down 71.06% from the prior year.
• Cash from Financing Activities grew to $19.7 million in Q1 2026, from -$240000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $26.3 million in Q2 2024 to a low of -$2.6 million in Q2 2025.
• A 5-year average of $5.7 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 818.29% — and 2025, when it sank 109.75%.
• Tracing ALLR's Cash from Financing Activities over 5 years: stood at $1.0 million in 2022, then plunged by 47.8% to $522000.0 in 2023, then jumped by 711.3% to $4.2 million in 2024, then tumbled by 105.67% to -$240000.0 in 2025, then soared by 8325.0% to $19.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $19.7 million (Q1 2026), -$240000.0 (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.